TARGET-G
Live / Registered — Registered (as of 17 Jun 2025)
What this means for you
Registered since 17 Jun 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98463731
- Registration number
- 7831428
- Mark type
- Stylized text
- Filed
- 22 Mar 2024
- Published for opposition
- 29 Apr 2025
- Registered
- 17 Jun 2025
- Attorney of record
- Subaru Ryan Kanesaka
Goods and services
- Class 042 — Scientific and technological services: Research and development in the field of bacteriology, cytology, antibody technology, chemistry, immunology, and gene expression systems; scientific research in the field of genetics and genetic engineering; DNA screening for scientific research purposes; research and development, product development advisory services, and scientific research advisory services relating thereto in the fields of protein, antibody, and microorganism scientific study, and the study of cells; structural and functional analysis of the genome with genome editing technology; DNA screening for scientific research purposes with genome editing technology; research and development, product development advisory services, and scientific research advisory services relating thereto in the field of genome editing technology; scientific research in the field of genetics and genetic engineering with genome editing technology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; technical advisory services relating to development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; information services, namely, providing information relating to the development of pharmaceuticals, cosmetics or foodstuffs, all with genome editing technology; scientific and technological services, namely, scientific testing, examination or research relating to medical treatment or medical technology with genome editing technology; information services, namely, providing information for scientific testing, examination or research purposes relating to medical treatment or medical technology with genome editing technology; scientific and technological services, namely, scientific testing or research relating to genome or gene to which genome editing technology is applied; scientific and technical research and technological development of bioinformatic tools in the fields of editing, modulation, modification, engineering, regulation, repair and therapy of gene, genome and cells to develop human pharmaceutical, biological preparations, and diagnostic products and services; research and development for the pharmaceutical industry and biotechnology industry with genome editing technology; research and development of biotechnology for others; research and development of genome editing technology for others; development of pharmaceutical preparations and medicines; biotechnology research; research and development in the field of genomics and biotechnology; technical advisory consulting services in the field of genomics and biotechnology; structural and functional analysis of genomes; scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy all to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; scientific study and research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy all to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; scientific and technological services, namely, design of bioinformatic algorithms for use in scientific and medical research in the fields of gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy all to develop human pharmaceutical and biological preparations to be delivered or applied ex vivo to human cells for use in human therapeutics and diagnostic products and services; testing, examination being inspection or research on agriculture, livestock breeding or fisheries
Owner
- Bio Palette Co., Ltd., Chiyoda-ku, JP
- Bio Palette Co., Ltd., Chiyoda-ku, JP
- Bio Palette Co., Ltd., Chiyoda-ku, JP
Prosecution history
- 28 Jan 2026 — TEAS SECTION 7 SURRENDER RECEIVED
- 14 Jan 2026 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 14 Jan 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 14 Jan 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 14 Jan 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Jun 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Jun 2025 — REGISTERED-PRINCIPAL REGISTER
- 29 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Apr 2025 — PUBLISHED FOR OPPOSITION
- 23 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 24 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 24 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 05 Dec 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED